These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 11925133)

  • 1. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
    Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
    Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
    Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
    Rose PG; Markman M; Bell JG; Fusco NL
    Gynecol Oncol; 2006 Aug; 102(2):236-9. PubMed ID: 16412499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
    Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):369-72. PubMed ID: 10985896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Rose PG; Rodriguez M; Waggoner S; Greer BE; Horowitz IR; Fowler JM; McGuire WP
    J Clin Oncol; 2000 Aug; 18(16):2957-62. PubMed ID: 10944128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
    Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
    Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.
    Rose PG; Maxson JH; Fusco N; Mossbruger K; Rodriguez M
    Gynecol Oncol; 2001 Aug; 82(2):323-8. PubMed ID: 11531287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
    Hwang JH; Yoo HJ; Lim MC; Seo SS; Park SY; Kang S
    Anticancer Drugs; 2012 Mar; 23(3):321-5. PubMed ID: 22156765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
    Rose PG; Blessing JA; Van Le L; Waggoner S
    Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
    Lyass O; Hubert A; Gabizon AA
    Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
    Brown JV; Peters WA; Rettenmaier MA; Karlan BY; Dillman RA; Smith MR; Drescher CW; Micha JP
    Gynecol Oncol; 2000 Dec; 79(3):495-8. PubMed ID: 11104627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
    Sood AK; Lush R; Geisler JP; Shahin MS; Sanders L; Sullivan D; Buller RE; Sorosky JI
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6080-5. PubMed ID: 15447993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study.
    Homesley HD; Blessing JA; Sorosky J; Reid G; Look KY
    Gynecol Oncol; 2005 Aug; 98(2):294-8. PubMed ID: 15975638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
    Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.